Nkarta, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:NKTX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -24.75 M-29.61 M-18.75 M-18.69 M-21.65 M-28.2 M -87.29 M Cash from investing activities -4.52 M54.34 M19.49 M25.39 M1.1 M15.91 M 61.9 M Cash from financing activities 184 K077 K064 K6 000 147 K Free cash flow -24.75 M-29.61 M-18.89 M-18.68 M-22.21 M-28.61 M -88.39 M

News

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta CEO Hastings sells $53,915 in NKTX stock

Nkarta (NKTX) president Nadir sells $11,693 in shares

Nkarta: Pushing Deeper Into A Discount Vs. Their Holdings, For No Real Reason (NKTX)

Stifel lowers Nkarta stock price target to $11 from $12, keeps Buy rating

Nkarta to present data on B-cell depleting therapy at rheumatology meeting

Nkarta (NKTX): Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Nkarta (NASDAQ:NKTX)

This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Alcoa (NYSE:AA), Americold Realty Trust (NYSE:COLD)

Nkarta stock rating downgraded at William Blair to Market Perform

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights